In: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006.


Teicoplanin is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. Limited data indicate that teicoplanin is poorly excreted into breastmilk. Because teicoplanin is not orally absorbed it is unlikely to adversely affect the breastfed infant. One infant was safely breastfed during maternal therapy with teicoplanin and ceftriaxone. Until more information becomes available, monitor the breastfed infant for gastrointestinal disturbances such as diarrhea, particularly in newborn and preterm infants.

Publication types

  • Review